References
- Segal BH, Bow EJ, Menichetti F. Fungal infections in nontransplant patients with hematologic malignancies. Infect Dis Clin North Am 2002; 16: 935–64.
- Walsh JT, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persis-tent fever and neutropenia. New Engl J Med 1999; 340: 764–771.
- Cagnoni PJ. Liposomal amphotericin B versus conven-tional amphotericin B in the empirical treatment of persistent-ly febrile neutropenic patients. J Antimicrob Chemother 2002; 49 (suppl S1):81-86.
- Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402–7.
- Cannon JP, Carey KW, Danziger LH. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid based amphotericin B formulations. Pharmacotherapy 2001; 21: 1107–14.
- EORTC International Antimicrobial Therapy Project Group. Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. J Clin Oncol 1983; 1: 597–603.
- Asciouglu S, Rex JH, de Pauw B et al. Defining oppor-tunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants:an international consensus. Clin Infect Dis 2002; 34: 7–14.
- Fanci R, Casini C, Leoni F, Ciolli S, Bosi A. Incidence and management of proven and probable fungal infections in patients with acute leukemia: a monocentric experience. J Chemother 2004; 16, 6: 557–60.
- Prentice HG, Hann I, Hebrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711–8.